According to the latest data released by the World Health Organization, more than 30 new coronal vaccines have entered the clinical trial stage in the world, and nine of them are in the phase III clinical trial stage. China accounts for more than half of the vaccines that have entered phase III clinical trials. Xinhua News Agency recently interviewed Chen Wei, winner of the national honorary title of “people’s hero”, academician of the Chinese Academy of engineering and researcher of the Academy of military medicine of the Academy of Military Sciences, and learned about the progress of the recombinant new crown vaccine developed by the Chinese Academy of Military Sciences. According to Chen Wei, the vaccine has independent intellectual property rights and advanced technology. Its outstanding feature is that it can not only have humoral immunity (antibodies and neutralizing antibodies), but also obtain cellular immunity. < / P > < p > the world’s first phase I clinical trial was carried out on March 16, and the phase III clinical trial is being effectively promoted. As the domestic epidemic situation has been effectively controlled, it is necessary to carry out phase III clinical trial across the country to conduct a larger scale evaluation of vaccine effectiveness and safety. Chen Wei: “our recombinant new crown vaccine has been ready for mass production since the phase I clinical trial. At present, the annual output of 300 million yuan can be achieved, and we are trying to expand production capacity. ” < p > < p > for the effective protection time after vaccination, Chen Wei said that it was only half a year since the isolation of the new coronavirus. “Our vaccine first entered phase I clinical trial in March in the world, and now we have only half a year’s data. At present, the injection in March is still effective. ” How long can its protection last? “At present, we can only infer from similar vaccines in the past. For example, the immune response of Ebola vaccine will decrease after six months of the first injection, and it will be effective for two years if the second injection is given in about six months. This is the data that can be used as reference. ” Chen Wei: “we are a genetic engineering vaccine, which is to find the most useful gene and make it into a vaccine. According to the current data analysis, the probability of this gene change is very low. Up to now, our recombinant coronavirus vaccine can completely cover the mutated new coronavirus. < / P > < p > in addition, since we are genetically engineered vaccines, we can use the current vaccines as the basic immunity in case of mutation and affect the protection effect. We can quickly make a more targeted vaccine to strengthen the immunity, just like supplementing the software upgrade. ” More Samsung devices can now run Android applications on PC through your phone